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Detailed measurements from the Mir and ISS long duration missions have documented 
losses in bone mineral density (BMD) from critical skeletal sub-regions. The most 
important BMD losses are from the femoral hip, averaging about -1.6%/mo integral to -
2.3%/mo trabecular. Importantly these studies have documented the wide range in 
individual BMD loss from -0.5 to -5%/mo. Associated elevated urinary Ca increases the 
risk of renal stone formation during flight, a serious impact to mission success. To date, 
countermeasures have not been satisfactory. 
 
The purpose of this study is to determine if the combined effect of anti-resorptive drugs 
plus the standard in-flight exercise regimen will have a measurable effect on preventing 
space flight induced bone loss (mass and strength) and reducing renal stone risk. To date, 
4 crewmembers have completed the flight portion of the protocol in which crewmembers 
take a 70-mg alendronate tablet once a week before and during flight, starting 17 days 
before launch. Compared to previous ISS crewmembers (n=14) not taking alendronate, 
DXA measurements of the spine, femur neck and total hip were significantly improved 
from -0.8 ± 0.5%/mo to 1.0 ±  1.1%/mo,  -1.1 ± 0.5%/mo to -0.2 ± 0.3%/mo,  -
1.1±0.5%/mo to 0.04±0.3%/mo respectively. QCT-determined trabecular BMD of the 
femur neck, trochanter and total hip were significantly improved from -2.7 ± 1.9%/mo to 
-0.2 ± 0.8%/mo, -2.2 ± 0.9%/mo to -0.3 ± 1.9%/mo and -2.3±1.0%/mo to -0.2±1.8%/mo 
respectively. Significance was calculated from a one-tailed t test. Resorption markers 
were unchanged, in contrast to measurements from previous ISS crewmembers that 
showed typical increases of 50-100% above baseline. Urinary Ca showed no increase 
compared to baseline levels, also distinct from the elevated levels of 50% or greater in 
previous crews.  
 
While these results are encouraging, the current n (4) is small, and the large SDs indicate 
that, while the means are improved, there is still high variability in individual response. 
Three additional crewmembers have been recruited to participate in this experiment, with 
expected completion in late 2011.       
 
https://ntrs.nasa.gov/search.jsp?R=20110008649 2019-08-30T15:13:36+00:00Z
